blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2242769

EP2242769 - ANTI-CADHERIN-11 EC1 DOMAIN ANTIBODIES FOR TREATING INFLAMMATORY JOINT DISORDERS [Right-click to bookmark this link]
Former [2010/43]CADHERIN-11 EC1 DOMAIN ANTAGONISTS FOR TREATING INFLAMMATORY JOINT DISORDERS
[2015/51]
StatusNo opposition filed within time limit
Status updated on  08.09.2017
Database last updated on 25.09.2024
Most recent event   Tooltip15.11.2019Lapse of the patent in a contracting state
New state(s): MK		published on 18.12.2019  [2019/51]
Applicant(s)For all designated states
Adheron Therapeutics, Inc.
200 Boston Avenue, Suite 1100
Medford, MA 02155 / US
[2014/08]
Former [2010/43]For all designated states
Synovex Corporation
200 Boston Avenue Suite 1100
Medford, MA 02155 / US
Inventor(s)01 / MCARTHUR, James, G.
94 Upland Road
Concord, MA 01742 / US
 [2010/43]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2016/44]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2013/37]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham
NG1 5GG / GB
Former [2010/43]Simpson, Mark Geoffrey
Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham
NG1 5DD / GB
Application number, filing date09700394.109.01.2009
[2010/43]
WO2009US00162
Priority number, dateUS20080010734P11.01.2008         Original published format: US 10734 P
[2010/43]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009089062
Date:16.07.2009
Language:EN
[2009/29]
Type: A2 Application without search report 
No.:EP2242769
Date:27.10.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 16.07.2009 takes the place of the publication of the European patent application.
[2010/43]
Type: B1 Patent specification 
No.:EP2242769
Date:02.11.2016
Language:EN
[2016/44]
Search report(s)International search report - published on:EP24.09.2009
ClassificationIPC:C07K16/28, A61K38/17, A61K38/00, A61K39/395, A61K31/519, A61K45/06, C07K16/18
[2015/51]
CPC:
C07K16/28 (EP,US); C07K16/18 (US); A61K31/519 (EP,US);
A61K39/3955 (US); A61K45/06 (US); A61P17/06 (EP);
A61P19/02 (EP); A61P29/00 (EP); C07K14/705 (EP,US);
A61K38/00 (EP,US); C07K2317/24 (EP,US); C07K2317/34 (EP,US);
C07K2317/515 (EP,US); C07K2317/74 (EP,US); C07K2317/76 (EP,US);
C07K2319/30 (EP,US); C07K2319/74 (EP,US) (-)
Former IPC [2010/43]C07K16/28, A61K38/17
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/44]
Former [2010/43]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:CADERHIN-11 EC1 DOMÄNE ANTIKÖRPER ZUR BEHANDLUNG ENTZÜNDLICHER GELENKSERKRANKUNGEN[2015/51]
English:ANTI-CADHERIN-11 EC1 DOMAIN ANTIBODIES FOR TREATING INFLAMMATORY JOINT DISORDERS[2015/51]
French:ANTICORPS ANTI-CADHÉRINE-11 EC1 ET PROCÉDÉS DE TRAITEMENT DE TROUBLES INFLAMMATOIRES DES ARTICULATIONS[2015/51]
Former [2010/43]CADHERIN-11-EC1-DOMÄNE-ANTAGONISTEN ZUR BEHANDLUNG ENTZÜNDLICHER GELENKSERKRANKUNGEN
Former [2010/43]CADHERIN-11 EC1 DOMAIN ANTAGONISTS FOR TREATING INFLAMMATORY JOINT DISORDERS
Former [2010/43]ANTAGONISTES DE CADHÉRINE-11 ET PROCÉDÉS DE TRAITEMENT DE TROUBLES INFLAMMATOIRES DES ARTICULATIONS
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase06.08.2010National basic fee paid 
06.08.2010Designation fee(s) paid 
06.08.2010Examination fee paid 
Examination procedure06.08.2010Examination requested  [2010/43]
24.09.2010Amendment by applicant (claims and/or description)
05.12.2012Despatch of a communication from the examining division (Time limit: M04)
05.04.2013Reply to a communication from the examining division
09.11.2015Cancellation of oral proceeding that was planned for 10.11.2015
10.11.2015Date of oral proceedings (cancelled)
08.12.2015Communication of intention to grant the patent
08.04.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.05.2016Communication of intention to grant the patent
22.09.2016Fee for grant paid
22.09.2016Fee for publishing/printing paid
22.09.2016Receipt of the translation of the claim(s)
Divisional application(s)EP16194905.2  / EP3181588
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.12.2012
Opposition(s)03.08.2017No opposition filed within time limit [2017/41]
Fees paidRenewal fee
25.01.2011Renewal fee patent year 03
25.01.2012Renewal fee patent year 04
25.01.2013Renewal fee patent year 05
27.01.2014Renewal fee patent year 06
27.01.2015Renewal fee patent year 07
27.01.2016Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY02.11.2016
EE02.11.2016
FI02.11.2016
HR02.11.2016
LT02.11.2016
LV02.11.2016
MC02.11.2016
MK02.11.2016
RO02.11.2016
SK02.11.2016
LU09.01.2017
MT09.01.2017
BG02.02.2017
NO02.02.2017
GR03.02.2017
IS02.03.2017
PT02.03.2017
[2019/51]
Former [2019/46]CY02.11.2016
EE02.11.2016
FI02.11.2016
HR02.11.2016
LT02.11.2016
LV02.11.2016
MC02.11.2016
RO02.11.2016
SK02.11.2016
LU09.01.2017
MT09.01.2017
BG02.02.2017
NO02.02.2017
GR03.02.2017
IS02.03.2017
PT02.03.2017
Former [2018/43]EE02.11.2016
FI02.11.2016
HR02.11.2016
LT02.11.2016
LV02.11.2016
MC02.11.2016
RO02.11.2016
SK02.11.2016
LU09.01.2017
MT09.01.2017
BG02.02.2017
NO02.02.2017
GR03.02.2017
IS02.03.2017
PT02.03.2017
Former [2018/01]EE02.11.2016
FI02.11.2016
HR02.11.2016
LT02.11.2016
LV02.11.2016
MC02.11.2016
RO02.11.2016
SK02.11.2016
LU09.01.2017
BG02.02.2017
NO02.02.2017
GR03.02.2017
IS02.03.2017
PT02.03.2017
Former [2017/43]EE02.11.2016
FI02.11.2016
HR02.11.2016
LT02.11.2016
LV02.11.2016
MC02.11.2016
RO02.11.2016
SK02.11.2016
BG02.02.2017
NO02.02.2017
GR03.02.2017
IS02.03.2017
PT02.03.2017
Former [2017/38]EE02.11.2016
FI02.11.2016
HR02.11.2016
LT02.11.2016
LV02.11.2016
RO02.11.2016
SK02.11.2016
BG02.02.2017
NO02.02.2017
GR03.02.2017
IS02.03.2017
PT02.03.2017
Former [2017/35]EE02.11.2016
FI02.11.2016
HR02.11.2016
LT02.11.2016
LV02.11.2016
RO02.11.2016
NO02.02.2017
GR03.02.2017
IS02.03.2017
PT02.03.2017
Former [2017/26]FI02.11.2016
HR02.11.2016
LT02.11.2016
LV02.11.2016
NO02.02.2017
GR03.02.2017
IS02.03.2017
PT02.03.2017
Former [2017/12]LV02.11.2016
Cited inInternational search[X]WO9957149  (ADHEREX TECHNOLOGIES INC [CA], et al) [X] 1-9,19-23,25-27,29-32,34-39,41,43-46,49-55,60,61 * abstract * * page 130, paragraph 2 * * page 131, paragraph 2 * * page 138, line 15 * * page 142, line 9 *;
 [A]WO0117557  (BRIGHAM & WOMENS HOSPITAL [US]) [A] 1-9,19-23,25-39,41-61 * abstract * * figure 3; claims 1-49 *;
 [X]WO2004048411  (ADHEREX TECHNOLOGIES INC [CA], et al) [X] 1-9,19-23,25-32,34-39,41,43-46,50,52-55,60,61 * claims 45,51,52,66 * * abstract * * page 112, paragraph 2 * * page 121, paragraph LAST * * page 133, line 8 *;
 [A]  - KIENER HANS P ET AL, "Building the synovium: cadherin-11 mediates fibroblast-like synoviocyte cell-to-cell adhesion.", ARTHRITIS RESEARCH & THERAPY 2005, (2005), vol. 7, no. 2, ISSN 1478-6362, pages 49 - 54, XP002528083 [A] 1-9,19-23,25-39,41-61 * abstract *

DOI:   http://dx.doi.org/10.1186/AR1495
 [A]  - KIENER HANS P ET AL, "Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro.", THE AMERICAN JOURNAL OF PATHOLOGY MAY 2006, (200605), vol. 168, no. 5, ISSN 0002-9440, pages 1486 - 1499, XP002528084 [A] 1-9,19-23,25-39,41-61 * abstract *

DOI:   http://dx.doi.org/10.2353/AJPATH.2006.050999
 [A]  - VALENCIA XAVIER ET AL, "Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes.", THE JOURNAL OF EXPERIMENTAL MEDICINE 20 DEC 2004, (20041220), vol. 200, no. 12, ISSN 0022-1007, pages 1673 - 1679, XP002528085 [A] 1-9,19-23,25-39,41-61 * abstract *

DOI:   http://dx.doi.org/10.1084/JEM.20041545
 [A]  - LEE DAVID M ET AL, "Cadherin-11 in synovial lining formation and pathology in arthritis.", SCIENCE (NEW YORK, N.Y.) 16 FEB 2007, (20070216), vol. 315, no. 5814, ISSN 1095-9203, pages 1006 - 1010, XP002528086 [A] 1-9,19-23,25-39,41-61 * abstract *

DOI:   http://dx.doi.org/10.1126/SCIENCE.1137306
Examination   - Saurabh D. Patel ET AL, "Type II Cadherin Ectodomain Structures: Implications for Classical Cadherin Specificity", Cell, (20060301), vol. 124, no. 6, doi:10.1016/j.cell.2005.12.046, ISSN 0092-8674, pages 1255 - 1268, XP055045706

DOI:   http://dx.doi.org/10.1016/j.cell.2005.12.046
by applicantUS5545806
 US5545807
 WO9713852
    - JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 2551 - 2555
    - JAKOBOVITS ET AL., NATURE, (1993), vol. 362, pages 255 - 258
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.